Overview

Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer

Status:
Recruiting
Trial end date:
2023-04-19
Target enrollment:
Participant gender:
Summary
Clinical Efficacy and Safety of EGFR-TKI Combined With Nimotuzumab in the Treatment of Leptomeningeal Metastases From Lung Cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Hui Bu
Treatments:
Nimotuzumab